MML Investors Services LLC Buys 5,299 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

MML Investors Services LLC lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 98.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,660 shares of the medical research company's stock after buying an additional 5,299 shares during the quarter. MML Investors Services LLC's holdings in Bio-Rad Laboratories were worth $3,502,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Strategic Financial Concepts LLC bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at $3,561,000. Lecap Asset Management Ltd. acquired a new stake in Bio-Rad Laboratories in the fourth quarter worth $510,000. Diversified Trust Co bought a new stake in Bio-Rad Laboratories in the fourth quarter valued at $958,000. DAVENPORT & Co LLC raised its holdings in shares of Bio-Rad Laboratories by 48.8% during the fourth quarter. DAVENPORT & Co LLC now owns 84,677 shares of the medical research company's stock valued at $27,817,000 after purchasing an additional 27,780 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Bio-Rad Laboratories by 95.6% during the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock worth $14,836,000 after purchasing an additional 21,669 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analyst Upgrades and Downgrades

BIO has been the topic of a number of research reports. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $380.20.

Bio-Rad Laboratories Stock Down 1.3 %

Shares of BIO traded down $3.15 during trading hours on Friday, reaching $237.28. 325,930 shares of the stock traded hands, compared to its average volume of 316,035. Bio-Rad Laboratories, Inc. has a 52 week low of $215.38 and a 52 week high of $387.99. The company has a market cap of $6.65 billion, a price-to-earnings ratio of -3.65 and a beta of 1.12. The stock has a fifty day simple moving average of $247.75 and a 200 day simple moving average of $305.85. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping the consensus estimate of $1.73 by $0.81. The firm had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The company's quarterly revenue was down 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.30 EPS. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.